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ABSTRACT
Expression of the SASH1 protein is reduced in a range of human cancers and 
has been implicated in apoptotic cancer cell death. This study investigated whether 
increasing SASH1 expression could be a useful therapeutic strategy in breast cancer. 
Ectopic SASH1 expression increased apoptosis in 7/8 breast cancer cell lines. 
Subsequent in silico connectivity screening demonstrated that the clinically approved 
antihistamine drug, chloropyramine, increased SASH1 mRNA levels. Chloropyramine 
has previously been shown to have anti-tumour activity in breast cancer in part 
through modulation of FAK signalling, a pathway also regulated by SASH1. This study 
demonstrated that chloropyramine increased SASH1 protein levels in breast cancer 
cells. Consistent with this the agent reduced cell confluency in 7/8 cell lines treated 
irrespective of their ER status but not apoptosis incompetent MCF7 cells. In contrast 
SASH1 siRNA-transfected breast cancer cells exhibited reduced chloropyramine 
sensitivity. The prognostic significance of SASH1 expression was also investigated 
in two breast cancer cohorts. Expression was associated with favourable outcome 
in ER-positive cases, but only those of low histological grade/proliferative status. 
Conversely, we found a very strong inverse association in HER2+ disease irrespective 
of ER status, and in triple-negative, basal-like cases. Overall, the data suggest that 
SASH1 is prognostic in breast cancer and could have subtype-dependent effects on 
breast cancer progression. Pharmacologic induction of SASH1 by chloropyramine 
treatment of breast cancer warrants further preclinical and clinical investigation.
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INTRODUCTION 
Breast cancer is the second most common cancer 
worldwide, comprising 25% of all female cancers. 
Current therapeutic strategies are based primarily on 
primary tumour histopathology. Expression of hormone 
(oestrogen (ER) and progesterone) and human epidermal 
growth factor 2 (HER2) receptors is routinely assessed 
in diagnostic practice, as these proteins are strongly 
prognostic and predict responsiveness to hormone- 
and HER2-targeted therapies, respectively. Owing to 
improved management strategies, the survival rate has 
increased in the past few decades, however breast cancer 
is still the second highest cause of cancer-associated 
death in women [1]. For patients who experience distant 
relapse, secondary disease becomes increasingly harder 
to control with each line of therapy, with fewer treatment 
options due to efficient clonal adaptation by the tumour 
in response to new selection pressures. A key research 
priority is to identify new tumour cell sensitivities and 
drug targets, along with companion diagnostic markers 
to enable further personalisation of therapy, achieving 
maximal efficacy while minimising over-treatment. 
Furthermore, deeper molecular and genetic understanding 
of breast tumourigenesis is intensifying the focus on 
drug repositioning as a means of capitalising on existing 
resources, and fast-tracking clinical development of ‘new’ 
treatments.
SAM and SH3 domain containing 1 (SASH1) was 
initially identified as a putative tumour suppressor gene, 
based on detection of significantly lower mRNA levels 
in lung, thyroid and colorectal cancers compared to 
adjacent normal tissue [2, 3]. Low expression correlates 
with poor prognosis in colon cancer [4] and glioma [5]. 
A tumour suppressive role would also be consistent with 
studies demonstrating that SASH1 depletion increases 
lung cancer cell line viability, proliferation and migration 
[3, 6–8], and several recent studies demonstrated that 
it opposes mesenchymal differentiation and invasive 
cell behaviour in hepatocarcinoma, thyroid and ovarian 
cancer cell lines [9–11]. The precise molecular functions 
of SASH1 in normal tissues and cancer are still being 
investigated, though it is known to localise to the nucleus, 
and its SAM and SH3 domains imply signalling, adaptor 
and/or molecular scaffold functions [12, 13]. Indeed, it can 
regulate signalling through focal adhesion kinase (FAK) 
and AKT/PI3K [9, 11] and overexpression promotes 
apoptosis [3, 6]. SASH1 mRNA and protein levels are also 
reduced in breast cancer compared to matching normal 
mammary epithelia [2, 14], with one study suggesting that 
promoter hypermethylation correlates with repression [14], 
but the expression and prognostic significance of SASH1 
have not yet been investigated in breast tumour cohorts 
with appreciable clinical annotation or statistical power.
In this study we used in silico connectivity mapping 
and in vitro modelling to identify drugs that could be 
repositioned to augment SASH1 expression in cancer. 
We found that the antihistamine chloropyramine induced 
SASH1-dependent cell death in a panel of breast cancer 
cell lines. In order to identify breast cancer subgroups that 
could potentially benefit from such a strategy, we analysed 
the relationships between SASH1 expression, genomic 
status and clinicopathologic parameters in three large 
breast tumour cohorts, identifying significant but subtype-
dependent relationships between SASH1 expression, 
relapse and survival. These data suggest that further 
studies investigating repositioning of chloropyramine are 
warranted.
RESULTS 
Increasing SASH1 expression is sufficient to 
induce breast cancer cell line death
We initially quantified SASH1 protein expression 
in eight breast cancer cell lines by immunoblot analysis. 
This revealed variable expression, with three high 
expressing cell lines, T47-D, BT-549 and MDA-MB-231, 
two moderately expressing lines, Hs578T and SUM-315 
and three low expressing lines MCF7, MDA-MB-361 
and MDA-MB-468 (Figure 1A–1B). SASH1 has been 
described as a tumour suppressor, with overexpression 
resulting in an increase in cell death in lung cancer, 
melanoma, osteosarcoma and glioma cell lines [3, 6–8]. 
To investigate this a SASH1-GFP fusion protein was 
transiently over-expressed in breast cancer cell lines. 
Overexpression resulted in cell death in 7 of the 8 lines 
tested (statistically significant in 5 lines), with only the 
Caspase 3-deficient MCF7 cells showing no response 
(Figure 2). 
Chloropyramine treatment is sufficient to induce 
SASH1 expression and apoptosis in breast 
cancer cell lines
Hypothesising that increasing SASH1 levels 
may be a novel approach to cancer therapy, we utilised 
a connectivity screen using the cmap database (Broad 
Institute [15]) to identify drugs that lead to induction 
of SASH1. This identified a direct correlation between 
chloropyramine treatment and SASH1 mRNA expression 
(p = 0.000005, z-score 2.431). Chloropyramine is a first 
generation reversible H1-receptor antagonist that is 
approved in several European countries for management 
of allergic conditions such as conjunctivitis and bronchial 
asthma. 
After validating the chloropyramine-mediated 
induction of SASH1 in breast cancer cell lines at the 
protein level (Figure 3), we investigated whether this 
treatment could mimic the effect of SASH1 over-
expression on cell growth and survival. Treatment with 
chloropyramine inhibited cell growth in 7 of the 8 lines 
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Figure 1: SASH1 protein expression in breast cancer cell lines. Breast cancer cell lines were analysed for expression of SASH1 
by immunoblotting. Representative immunoblot is shown in (A), and (B) shows densitometric quantification of SASH1 expression relative 
to β-actin. Data shown are means +/– standard deviation from three independent experiments, arbitrarily normalised to MCF7. 
Figure 2: Ectopic SASH1 expression increases cell death. (A) Confirmation of SASH1 overexpression by immunoblotting. Breast 
cancer cell lines were transfected with expression constructs encoding a pCMV6-SASH1-GFP fusion protein or pCMV6-GFP alone, 
then harvested after 48 h for lysate preparation and SASH1/β-actin immunoblotting. Over-expression (OE) (B) SASH1 overexpression 
increases breast cancer cell line death. Cell lines were transfected as above, then stained with Hoechst 33342 and propidium iodide (PI) 
after 48 h and imaged and quantified using Incell 2200. Data shown are the mean relative proportions of GFP-positive, PI-positive (dead 
and late apoptotic) cells +/– standard deviation from three independent experiments. Differences between SASH1-GFP and GFP control 
cultures were assessed using two-tailed t-tests. *p < 0.05, **p < 0.005.
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treated (Figure 4A–4H). To investigate whether this 
was due to induction of apoptosis, we analysed post-
treatment levels of Annexin V in the three most sensitive 
cell lines, T47-D, MDA-MB-231 and BT-549. All three 
lines exhibited an increase in Annexin V (Figure 4I–4K), 
indicating induction of apoptosis. To determine whether 
the chloropyramine-induced cell death was SASH1-
dependent, we transfected T47-D, MDA-MB-231 and BT-
549 cells with SASH1-targeted siRNA prior to treatment 
(Figure 5A). This experiment demonstrated that SASH1 
depletion partially rescued the cell death response in all 
three lines (Figure 5B–5D), suggesting chloropyramine-
induced cell death is at least in part dependent upon 
SASH1 function.
SASH1 mRNA and protein levels stratify 
outcome in breast cancer
Reasoning that negative or low SASH1 expression 
may be a predictive biomarker for chloropyramine, we 
assessed its prognostic significance in the Queensland 
follow-up cohort (n = 449 invasive breast tumours 
sampled in duplicate on tissue microarrays (TMAs), with 
clinical annotation including long-term survival outcome 
[16, 17]). After immunohistochemical (IHC) staining of 
the TMAs with a well-characterised SASH1 antibody, we 
observed reasonably homogeneous nuclear staining of 
breast tumour cells, and scored this as negative, weakly, 
moderately or strongly positive (Figure 6A; 0, 1, 2 or 3+, 
respectively). 
Next, we analysed the relationships between SASH1 
expression and breast cancer-specific survival by Kaplan-
Meier analysis, separating the cohort into clinically-
relevant subgroups. We found a strong association between 
3+ nuclear SASH1 and favourable outcome in ER+ cases 
(Figure 6B (i); p = 0.008; HR 1.7 [1.16–2.67]). The 
proportions of SASH1-high and –low cases were similar 
in ER+ subgroups with high or low proliferative activity 
(p = ns; data not shown), but stratification of outcome was 
restricted to ER+ tumours with low proliferative activity 
(low levels of Ki67, low mitotic score or low histological 
grade; Figures 6B (i–iv)) and those co-expressing 
progesterone receptor (Figure 6B (v)). Chi square analysis 
showed that SASH1 was moderately associated with ER 
status, but none of the other clinicopathologic parameters 
available (Table 1), suggesting independent prognostic 
value. Consistent with this, multivariate survival analysis 
of ER+ cases using a stepwise Cox regression model 
including HER2 status, Ki67 status, tumour size and 
histological grade revealed that SASH1 expression was 
independently associated with breast cancer specific 
survival (BCSS) (Table 2; HR = 0.45; 95% confidence 
interval 0.27–0.77; p = 0.0037). 
We also analysed relapse-free survival in ER+ cases 
with high and low relative expression of SASH1 mRNA 
by meta-analysis of breast cancer gene expression data 
from the KM plotter database [18]. Consistent with our 
IHC analyses, higher expression of SASH1 was associated 
with better outcome in ER+ cases of luminal A molecular 
subtype, but not luminal B (more proliferative) cases, 
Figure 3: Chloropyramine increases SASH1 expression in breast cancer cell lines. (A–H) Cells were treated with 25 or 50 μM 
chloropyramine for 24 h, then lysates were prepared and SASH1 protein expression was analysed using immunoblotting. Immunoblot band 
intensities were quantified relative to β-actin in three independent experiments. The reproducibility and significance of changes in SASH1 
expression with treatment were assessed using two-tailed t-tests. *p < 0.05, **p < 0.005.
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Table 1: Relationships between SASH1 protein expression and clinicopathologic indicators in 
breast cancer using the Queensland follow-up (QFU) cohort 
n % cases p 
valueSASH1 staining: Total Negative weak-mod strong negative weak-mod strong
Histological type
IDC 228 56 79 93 24.6 34.6 40.8
ns
Lobular/variants 44 9 17 18 20.5 38.6 40.9
Mixed ducto-lob 31 8 10 13 25.8 32.3 41.9
Mixed 34 4 13 17 11.8 38.2 50.0
Metaplastic 15 4 6 5 26.7 40.0 33.3
Special types 27 6 13 8 22.2 48.1 29.6
n 379
Grade
1 51 8 18 25 15.7 35.3 49.0
ns2 182 43 72 67 23.6 39.6 36.83 146 36 48 62 24.7 32.9 42.5
n 379
Age
> 50 yr 250 54 94 102 21.6 37.6 40.8
ns≤ 50 yr 119 27 40 52 22.7 33.6 43.7
n 369
Lymph node 
status
Negative 113 28 38 47 24.8 33.6 41.6
nsPositive 98 23 46 29 23.5 46.9 29.6
n 211
Tumour size
< 2 cm 157 43 49 65 27.4 31.2 41.4
ns2–5 cm 141 25 57 59 17.7 40.4 41.8> 5 cm 29 5 11 13 17.2 37.9 44.8
n 327
Lymphovascular 
invasion
Absent 283 66 107 110 23.3 37.8 38.9
nsPresent 95 20 31 44 21.1 32.6 46.3
n 378
Lymphocytic 
infiltrate
Absent 136 34 55 47 25.0 40.4 34.6
nsMild 162 36 53 73 22.2 32.7 45.1Moderate-severe 80 17 30 33 21.3 37.5 41.3
n 378
Central scarring/
fibrosis
Absent 337 77 124 136 22.8 36.8 40.4
nsPresent 42 10 14 18 23.8 33.3 42.9
n 379
Tumour border
Infiltrative 324 72 114 138 22.2 35.2 42.6
nsPushing 55 15 24 16 27.3 43.6 29.1
n 379
Ki67 expression 
(20% threshold)
Low 307 73 115 119 23.8 37.5 38.8
nsHigh 53 10 16 27 18.9 30.2 50.9
n 360
HER2 status 
(CISH)
Negative 343 81 125 137 23.6 36.4 39.9
nsPositive 39 7 12 20 17.9 30.8 51.3
n 382
ER status Positive 285 58 110 117 20.4 38.6 41.1
0.0035Negative 82 28 17 37 34.1 20.7 45.1
n 367
TN status
Non-TNBC 311 64 115 132 20.6 37.0 42.4
nsTNBC 68 22 22 24 32.4 32.4 35.3
n 379
Other prognostic 
subgroups
HER2+ 38 7 12 19 18.4 31.6 50.0
ns
HR+/HER2-neg (Ki67-high) 235 56 88 91 23.8 37.4 38.7
HR+/HER2-neg (Ki67-low) 23 1 9 13 4.3 39.1 56.5
TN (basal-like) 54 18 17 19 33.3 31.5 35.2
TN (non-basal) 12 3 5 4 25.0 41.7 33.3
n 362
p Values shown are from chi square or Fisher’s exact tests.
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Figure 4: Chloropyramine induces dose-dependent reduction of breast cancer cell line growth that involves apoptosis. 
(A–H) Changes in adherent breast cancer cell line confluence following chloropyramine treatment. Cells were treated with chloropyramine 
for 96 h and imaged using light microscopy IncuCyte ZOOM system and digitally analysed to assess confluence relative to an untreated 
control culture. (I–K) Chloropyramine induces apoptosis in breast cancer cell lines. Cells were stained with propidium iodide and an 
Annexin V-FITC antibody conjugate 48 h post-chloropyramine treatment, and analysed by flow cytometry. All data shown are means 
+/– the standard deviation from three independent experiments. Statistical analysis was performed using two-tailed t-tests; *p < 0.05, 
**p < 0.005, ***p < 0.0005.
Table 2: Prognostic value of nuclear SASH1 expression in ER-positive breast cancer over 25 years
Covariates
Univariatea Multivariateb
HR 95% CI p value HR 95% CI p value
HER2 3.23 1.29–8.07 < 0.0001 2.45 1.21–4.98 0.0134
Ki67 1.87 0.88–3.95 0.0325 2.38 1.88–4.76 0.0150
SASH1 0.54 0.35–0.82 0.0068 0.45 0.27–0.77 0.0037
Size 2.32 1.52–3.53 0.0002 1.97 1.97–3.22 0.0078
Grade 3.17 1.75–5.76 0.0085 - - ns
Univariate and multivariate analysis of factors associated with breast cancer-specific survival among 223 ER+ cases in the 
Queensland Follow-up Cohort. (a), Kaplan-Meier analysis with the Log-rank test; (b) Stepwise Cox proportional hazards 
regression.
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and also in ER/PR+ but not ER+/PR- cases (Figure 6C). 
Multivariate analysis demonstrated that this association 
was independent of ERBB2 (HER2) or MKI67 (Ki67) 
expression (Table 3; p = 0.0032; HR 0.74).
Interestingly, SASH1 mRNA expression was 
inversely associated with relapse-free survival ER-negative 
and triple-negative basal-like cases (TNBL; Figure 7A), 
though this was not significant in a multivariate model 
(Table 3). Similarly, SASH1 was inversely associated with 
outcome in HER2+ disease (Figure 7B; p < 0.0001; HR 
3.26), independent of Estrogen Receptor 1 (ESR1) and 
MKI67 (Table 3; p = 0.0002; HR 3.07). The relationship 
was particularly striking for HER2+/ER+ cases where 
low SASH1 was associated with nearly 100% survival 
(p = 0.0002; HR 0.06). TNBL and HER2+ subgroup 
sizes in the QFU cohort were not conducive to statistical 
analysis (n = 54 and 38, respectively). 
DISCUSSION 
Based on its association with favourable prognosis 
in multiple human malignancies [2–8, 19] and adverse 
effects on cancer cell line viability and invasiveness 
in vitro [3, 6–8], SASH1 has been proposed as a tumour 
suppressor [2–4, 6, 8, 14, 20, 21]. Consistent with this, we 
found that ectopic expression of SASH1 reduced breast 
cancer cell line viability, and so we hypothesised it could 
be involved in processes required for maintaining cancer 
cell viability in vivo, and that increasing its expression 
could be a novel treatment strategy. 
To identify drug candidates with this capability, 
we performed in silico connectivity mapping using the 
cmap database (Broad Insitute [15]) and identified the 
antihistamine chloropyramine as a candidate SASH1 
inducer. Others have shown that chloropyramine reduces 
survival of cell lines from melanoma, neuroblastoma, 
breast and pancreatic cancers, involving inhibition of 
FAK and VEGFR3 signalling [22–26]. Interestingly, 
SASH1 has also been implicated in modulation of FAK 
signalling [9]. Consistent with the connectivity screen, 
chloropyramine induced SASH1 expression in seven 
of the eight breast cancer cell lines tested, and reduced 
the viability of six lines. Transfecting the three most 
sensitive lines with SASH1 siRNA prior to treatment 
partially rescued the cytotoxic response, suggesting that 
chloropyramine-induced cancer cell line death is at least 
partly mediated by SASH1. There is at least one existing 
report suggesting that chloropyramine can reduce breast 
cancer xenograft growth in vivo [26], though additional 
preclinical studies are required to more comprehensively 
characterise the anti-tumour activity of the agent.
If chloropyramine were to be considered for therapy, 
it would be important to establish which patient group may 
benefit. The prognostic significance of SASH1 expression 
is less characterised in breast cancer compared with other 
malignancies, so we investigated this using two clinically-
annotated tumour cohorts. Overall we found that SASH1 
was associated with favourable prognosis, but stratifying 
the cases based on ER status revealed that this was driven 
by the more prevalent ER-positive cases (75–80% of the 
cohorts analysed), and SASH1 expression was inversely 
associated with outcome in ER-negative, TNBL and 
HER2+ breast cancers. Thus although SASH1 has been 
coined a tumour suppressor, our findings suggest that this 
Figure 5: SASH1 depletion partially rescues chloropyramine-induced apoptosis in breast cancer cell lines. (A) Cells 
were transfected with negative control or SASH1 esiRNAs. After 72 h, cell lysates were prepared and SASH1 expression was analysed 
relative to β-actin by immunoblotting. Knockdown (KD). (B–D) Cells were transfected as above, and chloropyramine was added 24 h post-
transfection. Cultures were imaged by light microscopy IncuCyte ZOOM system and digitally analysed to assess confluence relative to the 
untreated control at 96 h post-treatment. Data shown are means +/– the standard deviation from three independent experiments. t-tests were 
used to compare cell confluence with and without SASH1 depletion at each of the chloropyramine doses; *p < 0.05.
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may be oversimplifying its role and that context is critical. 
Indeed, interrogating other KM Plotter cancer datasets 
we found strong associations between SASH1 mRNA 
expression and better overall survival in lung cancer but 
very poor outcome in gastric cancer (data not shown).
Breast cancer management has improved 
substantially over the last few decades, but in Australia, 
the US and UK, 15–20% of patients still do not survive 
10 years after diagnosis [27, 28]. This amounts to a large 
proportion of cancer-related morbidity and mortality 
and cost to the public health sector. Tumours that do not 
respond to current first-line therapies are likely to be 
more complex and heterogeneous. Disease control in the 
future will depend on an increased understanding of the 
molecular biology of the disease, leading to identification 
of novel personalised medicine therapy approaches linked 
to companion diagnostics. In silico connectivity screening 
provides a means to fast-track the identification of 
Figure 6: High SASH1 expression is an independent marker of favourable prognosis in ER-positive breast cancer, 
particularly for low grade and PR co-expressing tumours. (A) Representative SASH1 IHC images of breast cancer tissue 
microarray cores. Two grade-3 (G3) invasive ductal carcinomas (IDC) with negative and strongly positive nuclear SASH1 expression are 
shown at low and high magnification. (B) Kaplan-Meier analysis of the relationships between SASH1 protein expression and breast cancer-
specific survival (BCSS) in ER+ breast cancer (defined using current clinical diagnostic (Dx) criteria of positivity in at least 1% of tumour 
cell nuclei). Across all 275 cases, 3+ SASH1 staining was associated with better long-term survival (i), but this result was driven by tumours 
characterised by relatively low levels of proliferation (ii, low Ki67 expression; iii, low mitotic score (ms); iv, low-grade) or those with 
strong co-expression of PR (v). (C) Stratification of relapse-free survival according to high or low SASH1 mRNA expression (KM Plotter 
database). (i) ER+, luminal A and luminal B cohorts defined by gene expression data. (ii) ER+, ER+/PR+ and ER+/PR- cohorts defined by 
clinical diagnostic criteria. Log-rank p values and hazard ratios (HR; 95% confidence intervals in parentheses) are indicated.
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gene-drug associations and drug repurposing 
opportunities. In silico mapping of associations between 
induction of SASH1 and ‘off-the-shelf’ drugs identified 
a novel candidate, chloropyramine, with antitumour 
activity in vitro. Chloropyramine and other first-generation 
H1 antagonists are sedating because they cross the 
blood-brain-barrier, and were therefore superseded by 
peripherally-acting agents for the treatment of allergy. 
Given that brain uptake can be desirable in molecular 
oncology and chloropyramine is otherwise well-tolerated, 
the potential application for this or structurally related 
agents for low toxicity treatment of breast and other 
cancers deserves further mechanistic and preclinical 
investigation. Furthermore, phase 0 and dose-finding 
phase I, neoadjuvant, biomarker-driven clinical trials 
could allow us to confirm pharmacodynamic induction of 
SASH1 by chloropyramine that would underpin further 
repurposing studies of the agent in the future. 
Table 3: Multivariate Cox regression analysis of factors associated with 15 year breast cancer 
relapse-free survival in the KM Plotter database [18]
ER-positive HER2-positive Triple-negative, basal-like
Transcript HR I 95% CI l p value HR 95% CI p value HR 95% CI p value
SASH1 0.74 0.61–0.9 0.0032 3.07 1.71–5.51 0.0002 1.78 0.91–3.49 0.09
MKI67 1.39 1.09–1.75 0.0068 ns ns
ERBB2 1.20 0.94–1.54 ns - - - - - -
ESR1 - - - 0.55 0.32–0.97 0.038 - - -
ER, PR and HER2 status was determined using clinical diagnostic criteria. Expression of SASH1, MKI67 (Ki67), ERBB2 (HER2) 
and ESR1 (ER) mRNA was divided according to best statistical stratification. CI, confidence interval; HR, hazard ratio.
Figure 7: High SASH1 expression is an independent marker of poor prognosis in ER-negative and HER2-positive 
breast cancer subtypes. Kaplan-Meier analysis of relapse-free survival (RFS) according to high or low SASH1 mRNA expression (KM 
Plotter database). (A) ER-negative subgroups. (B) HER2+ subgroups. ER and HER2 status defined by clinical diagnostic criteria. Log-rank 
p values and hazard ratios (HR; 95% confidence intervals in parentheses) are indicated.
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MATERIALS AND METHODS
Cell culture and transfection
Breast cancer cell lines were cultured at 37°C 
with 5% CO2 in RPMI with 10% FCS (MDA-MB-231, 
MDA-MB-361, T47-D, and BT-549), DMEM with 10% 
FCS (MCF7, MDA-MB-468, and Hs578T) or Ham’s 
F12 with 5% FBS and 10 μg/ml recombinant human 
epidermal growth factor (SUM1315). Insulin was 
supplemented at 0.01 mg/mL for the MCF7, Hs578T, 
BT-549, T47-D, and SUM1315 cell lines. Cells were 
routinely passaged with trypsin and maintained at 
low passage. Chloropyramine (Sigma-Aldrich) was 
added to adherent cultured cells 24 hours after seeding 
at the indicated concentrations (0–100 μM). Cell line 
authentication by STR profiling was performed at QIMR 
Berghofer, with comparison to Children’s oncology 
group cell culture and Xenograft repository (http://www.
cogcell.org).
For siRNA experiments, esiRNAs (Sigma) targeting 
SASH1 or non-specific control oligos were transfected 
using RNAiMax (Invitrogen) as per the manufacturer’s 
instructions. Double-transfections were performed 
24 hours apart and samples were analysed 72 hours after 
the initial transfection where optimal SASH1 depletion 
was observed. For overexpression studies, the full-
length SASH1 cDNA was cloned into the mammalian 
expression vector pCMV6 (Origene). Three μg of DNA 
(SASH1-GFP or GFP) and 6 μL of Lipofectamine 2000 
(Invitrogen) were used to transfect cells in a T25 flask, as 
per the manufacturer’s instructions. Cells were harvested 
24–48 h post-transfection for optimal overexpression and 
death assessment as indicated in figure legends. 
Immunoblotting
Immunoblotting was carried out as described 
previously [29]. Briefly, cells were lysed (20 mM Hepes 
pH 8.0, 150 mM KCl, 5% glycerol, 10 mM MgCl2, 
0.5 mM EDTA, 0.02% NP-40, freshly supplemented 
with NaF, NaVO4, PMSF and protease inhibitors) and 
sonicated. Lysates were cleared by centrifugation and 
protein concentrations were estimated using the Bradford 
assay (Bio-Rad). Typically 50 µg of protein lysate was 
resolved on Bolt 4–12% gradient gels (Invitrogen) and 
proteins were transferred to nitrocellulose membrane (Bio-
Rad). Membranes were blocked in 2% fish skin gelatin, 
1% tween-20 in PBS (Sigma) for 1 h and incubated 
with primary antibodies overnight 4°C in the same 
buffer. Following incubation with secondary antibodies, 
membranes were visualised using a Li-COR Odyssey 
infrared scanner. Fluorescence intensity was quantified 
relative to a loading control (β-actin or Histone H3) using 
Image J software. 
Cell death assay
Following incubation of cells with the indicated 
treatments, propidium iodide (10 μg/ml) and Hoechst 
(1 μg/ml) were added 30 min before imaging. Cells were 
imaged on an IN Cell Analyzer 2200 (GE Healthcare; 
10× objective). Live/dead cell analysis was performed 
using IN Cell analysis software. 
Cell confluency assay
Cells were seeded at 2,500 cells per well in 96 well 
plates (Nunc). Cells were allowed to adhere for 24 h 
before chloropyramine addition and then imaged every 
2 hours for 96 hours in an IncuCyte ZOOM® live cell 
imager (Essen Bioscience) to calculate confluence.
Annexin V/Propidium iodide (PI) analysis
Annexin V/PI staining was carried out as described 
previously [30]. Briefly, treated or untreated cells 
(adherent and floating) were harvested using trypsin and 
centrifugation, washed in PBS and then stained according 
to the Promega Annexin V-FITC apoptosis detection 
kit protocol. Annexin V-positive (apoptotic) cells were 
detected using a Gallios flow cytometer system and 
quantified with Flow Jo software. 
Drug screen with connectivity mapping
A gene expression connectivity mapping approach 
was employed to identify candidate compounds that 
may induce SASH1 expression. SASH1 was mapped 
to Affymetrix HG-U133A probeset IDs to form a query 
gene signature. This was compared to the reference drug 
expression profiles in the CMap02 database using the 
sscMap algorithm [31, 32]. Compounds with statistically 
significant positive connection to the query gene signature 
were selected as candidate SASH1 inducing drugs for 
further laboratory validation as described. 
Immunohistochemistry (IHC) and tissue 
microarray (TMA) analysis
SASH1 protein expression in breast cancer was 
investigated by IHC analysis of the Queensland follow-up 
(QFU) resource, comprising TMAs of 449 invasive breast 
carcinomas (sampled in duplicate) and associated clinical 
data, including survival outcomes of over 20 years [33]. 
The use of patient data and clinical samples in this study 
were approved by human research ethics committees of 
the University of Queensland and the Royal Brisbane and 
Women’s Hospital (RBWH). 
Four μm TMA sections were processed in a 
decloaker for antigen retrieval in EDTA buffer (pH 8.8) 
Oncotarget72817www.impactjournals.com/oncotarget
for 15 minutes, and then IHC was performed using an 
anti-SASH1 antibody (Sigma Prestige HPA029947; 
1:850), and the Mach 1 Universal HRP-Polymer Detection 
kit (Biocare Medical). Haematoxylin-counterstained, 
mounted sections were then scanned at 40 x magnification 
on an Aperio AT Turbo slide scanner (Leica Biosystems). 
Digital images of individual tissue cores were scored by 
a qualified Pathologist (AMM) according to tumour cell 
nuclear staining intensity. Using the maximum score of 
duplicate tissue cores for each case, associations between 
SASH1 expression and clinicopathologic variables were 
investigated using chi-square and log-rank tests (GraphPad 
Prism v6). 
In silico analysis of SASH1 mRNA prognostic 
significance
The relationships between SASH1 mRNA expression 
and relapse-free survival were analysed using the KM 
plotter breast cancer database [18]. Three different SASH1 
probes were analysed; representative data from the ‘JetSet’ 
optimal probe are presented in this paper [34].
Statistical analyses
Most statistical tests were performed using Graph 
Pad Prism V6. Associations between breast tumour 
SASH1 expression and clinicopathologic variables were 
investigated using chi square or Fisher’s exact tests. 
Relationships between breast tumour SASH1 expression 
and relapse-free or overall survival were represented with 
Kaplan-Meier curves and analysed using the log-rank 
test. Analysis of SASH1-mediated changes in apoptosis 
and proliferation, and SASH1 expression following 
chloropyramine treatment were investigated with students 
two-tailed t-tests. For multivariate analysis of SASH1 
mRNA prognostic significance was performed using the 
parameters available (MKI67 and ERBB2 expression) and 
inbuilt function in the KM plotter database [18]. 
For multivariate analysis of SASH1 protein 
prognostic significance in ER+ breast cancer, we 
performed stepwise Cox regression analysis using 
MedCalc® software (v13.2) including HER2 status 
(determined by SISH according to diagnostic criteria), 
Ki67 status (nuclear staining in at least 20% tumour cells), 
histological grade (assessed by an experienced Pathologist 
(SRL) and tumour size (derived from clinical pathology 
reports). These data were complete for 223 ER+ cases. 
p Values > 0.05 were considered significant.
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